Skip to main content
. Author manuscript; available in PMC: 2008 Dec 14.
Published in final edited form as: Brain Res. 2007 Sep 22;1185:256–265. doi: 10.1016/j.brainres.2007.09.034

Figure 3. AAV2 IGF-1 delivery delayed disease onset and extended survival selectively in male SOD1G93A mice.

Figure 3

No change in disease onset was noted for female SOD1G93A mice (B), while a significant increase in onset of 19.0 days was seen in male SOD1G93A mice (A). However, no change was observed in disease duration, the time between disease onset and end-stage, in male (C) or female (D) SOD1G93A mice. AAV2 IGF-1 significantly increased survival in male SOD1G93A mice by 12.3 days compared to the AAV2 GFP group (E), while no effect was found in females (F).